Tenvie Therapeutics develops small-molecule drugs aimed at neurological diseases, with a focus on molecules designed to cross the blood-brain barrier and reach the central nervous system effectively. Its leading strategy is to optimize molecular delivery properties so CNS penetration is improved, maximizing benefits for patients. The company maintains a diverse pipeline of proprietary assets, including programs acquired from Denali Therapeutics, and monetizes its work by advancing these CNS-targeted therapies in clinical development. Led by President and Chief Scientific Officer Tony Estrada, the team emphasizes CNS drug development expertise to pursue patient-focused outcomes.
Company Size
51-200
Company Stage
Early VC
Total Funding
$200M
Headquarters
Brisbane, California
Founded
2025
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Hybrid Work Options
Tenvie Therapeutics promotes Tony Estrada, phd, to Chief Executive Officer.
In Q1 2025, biopharma venture funding surged, with Verdiva Bio launching with a $411 million series A, co-led by Forbion and General Atlantic, to develop therapies for obesity and cardiometabolic diseases. Other notable funding rounds included Aviceda Therapeutics' $208 million series C, Abcuro's $200 million series C, Windward Bio's $200 million series A, and Tenvie Therapeutics' $200 million seed funding.
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates.
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team...